J. Blake Bartlett

3.8k total citations · 1 hit paper
46 papers, 3.0k citations indexed

About

J. Blake Bartlett is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, J. Blake Bartlett has authored 46 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Hematology, 27 papers in Molecular Biology and 19 papers in Oncology. Recurrent topics in J. Blake Bartlett's work include Multiple Myeloma Research and Treatments (31 papers), Protein Degradation and Inhibitors (21 papers) and Cancer Treatment and Pharmacology (10 papers). J. Blake Bartlett is often cited by papers focused on Multiple Myeloma Research and Treatments (31 papers), Protein Degradation and Inhibitors (21 papers) and Cancer Treatment and Pharmacology (10 papers). J. Blake Bartlett collaborates with scholars based in United Kingdom, Switzerland and United States. J. Blake Bartlett's co-authors include Angus Dalgleish, Keith Dredge, Peter Schäfer, David Stirling, George W. Muller, Lei Wu, Roger Chen, Mary Adams, Ling Lu and Troy Carter and has published in prestigious journals such as Journal of Clinical Oncology, Nature reviews. Cancer and Blood.

In The Last Decade

J. Blake Bartlett

43 papers receiving 2.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The evolution of thalidomide and its IMiD derivatives as anticancer agents

2004 632 citations J. Blake Bartlett, Keith Dredge et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
J. Blake Bartlett United Kingdom	20	1.7k	1.6k	1.2k	560	552	46	3.0k
Boris K. Lin United States	26	2.4k 1.4×	2.8k 1.7×	1.6k 1.3×	543 1.0×	485 0.9×	50	4.4k
Andrew A. Lane United States	24	1.0k 0.6×	2.2k 1.4×	1.2k 1.1×	355 0.6×	689 1.2×	109	4.0k
David Flowers United States	20	988 0.6×	1.7k 1.1×	933 0.8×	330 0.6×	524 0.9×	43	3.2k
Richard LeBlanc Canada	20	2.2k 1.3×	2.2k 1.4×	1.5k 1.3×	308 0.6×	302 0.5×	107	3.2k
Thomas Kindler Germany	27	1.7k 1.0×	1.5k 0.9×	615 0.5×	768 1.4×	342 0.6×	78	3.0k
Daruka Mahadevan United States	24	693 0.4×	834 0.5×	634 0.5×	680 1.2×	410 0.7×	70	2.1k
Andrew J. Yee United States	26	1.0k 0.6×	1.4k 0.9×	1.1k 0.9×	250 0.4×	230 0.4×	127	2.3k
Anupriya Agarwal United States	28	1.7k 1.0×	1.4k 0.9×	497 0.4×	1.2k 2.1×	537 1.0×	85	3.1k
Kristina Anderson Sweden	21	2.1k 1.3×	2.1k 1.3×	891 0.8×	545 1.0×	1.1k 2.0×	30	4.1k
Claudia Scholl Germany	32	2.0k 1.2×	2.7k 1.7×	688 0.6×	676 1.2×	289 0.5×	72	4.2k

Countries citing papers authored by J. Blake Bartlett

Since Specialization

Citations

This map shows the geographic impact of J. Blake Bartlett's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Blake Bartlett with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Blake Bartlett more than expected).

Fields of papers citing papers by J. Blake Bartlett

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Blake Bartlett. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Blake Bartlett. The network helps show where J. Blake Bartlett may publish in the future.

Co-authorship network of co-authors of J. Blake Bartlett

This figure shows the co-authorship network connecting the top 25 collaborators of J. Blake Bartlett. A scholar is included among the top collaborators of J. Blake Bartlett based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Blake Bartlett. J. Blake Bartlett is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Song, Qingxuan, Deeksha Vishwamitra, Nikoletta Lendvai, et al.. (2024). Preclinical Analysis of Ciltacabtagene Autoleucel Combination Strategies with T Cell Bispecifics and Daratumumab to Support Optimization of Clinical Benefit in Myeloma Patients. Blood. 144(Supplement 1). 7167–7167.

Jayaram, Lata, Paul T. King, John E. Hunt, et al.. (2023). Evaluation of high dose N- Acetylcysteine on airway inflammation and quality of life outcomes in adults with bronchiectasis: A randomised placebo-controlled pilot study. Pulmonary Pharmacology & Therapeutics. 84. 102283–102283. 11 indexed citations

Cartier, Shannon, Bin Zhang, Virginia M. Rosen, et al.. (2015). Relationship between Treatment Effects on Progression-Free Survival and Overall Survival in Multiple Myeloma: A Systematic Review and Meta-Analysis of Published Clinical Trial Data. Oncology Research and Treatment. 38(3). 88–94. 24 indexed citations

Lopez‐Girona, Antonia, Daniel Heintel, Derek Mendy, et al.. (2011). Lenalidomide downregulates the cell survival factor, interferon regulatory factor‐4, providing a potential mechanistic link for predicting response. British Journal of Haematology. 154(3). 325–336. 137 indexed citations

Henry, Jake Y., Ling Lu, Mary Adams, et al.. (2011). Lenalidomide enhances the anti‐prostate cancer activity of docetaxel in vitro and in vivo. The Prostate. 72(8). 856–867. 18 indexed citations

Henry, Jake Y., Lingeng Lu, Mark E. Adams, et al.. (2010). Effect of lenalidomide on the antiprostate cancer activity of docetaxel in vitro and in vivo.. Journal of Clinical Oncology. 28(15_suppl). e13155–e13155. 1 indexed citations

Zhang, Liang, Zhengzi Qian, Zhen Cai, et al.. (2009). Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo. American Journal of Hematology. 84(9). 553–559. 120 indexed citations

Bartlett, J. Blake, et al.. (2009). Could an underlying hearing loss be a significant factor in the handicap caused by tinnitus?. Noise and Health. 11(44). 156–156. 63 indexed citations

Galustian, Christine, B Meyer, Marie‐Christine Labarthe, et al.. (2008). The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunology Immunotherapy. 58(7). 1033–1045. 324 indexed citations

10.

Jhavar, Sameer, J. Blake Bartlett, Gyula Kovács, et al.. (2008). Biopsy tissue microarray study of Ki-67 expression in untreated, localized prostate cancer managed by active surveillance. Prostate Cancer and Prostatic Diseases. 12(2). 143–147. 31 indexed citations

11.

Lu, Ling, Faribourz Payvandi, Lei Wu, et al.. (2008). The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions. Microvascular Research. 77(2). 78–86. 183 indexed citations

12.

Bartlett, J. Blake, Ling Lu, Faribourz Payvandi, et al.. (2007). The anticancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions. Molecular Cancer Therapeutics. 6. 2 indexed citations

13.

Poucher, Simon M., S Freeman, J. Blake Bartlett, et al.. (2007). An assessment of the in vivo efficacy of the glycogen phosphorylase inhibitor GPi688 in rat models of hyperglycaemia. British Journal of Pharmacology. 152(8). 1239–1247. 7 indexed citations

14.

Zhang, Linghua, Ling Lu, Lei Wu, et al.. (2006). VEGFr inhibitor YN968D1 xenograft dose response studies against human colon cancer Ls174t and HT29. Cancer Research. 66. 415–415. 13 indexed citations

15.

Freeman, S, et al.. (2006). Sensitivity of glycogen phosphorylase isoforms to indole site inhibitors is markedly dependent on the activation state of the enzyme. British Journal of Pharmacology. 149(6). 775–785. 22 indexed citations

16.

Evans, Charles, Alexander G. Heriot, J. Blake Bartlett, et al.. (2006). The correlation between colorectal cancer rates of proliferation and apoptosis and systemic cytokine levels; plus their influence upon survival. British Journal of Cancer. 94(10). 1412–1419. 45 indexed citations

17.

Dredge, Keith, Simon P. Robinson, Linghua Zhang, et al.. (2005). Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. Microvascular Research. 69(1-2). 56–63. 225 indexed citations

18.

Bartlett, J. Blake, et al.. (2005). Recent clinical studies of the immunomodulatory drug (IMiD®) lenalidomide. British Journal of Cancer. 93(6). 613–619. 50 indexed citations

19.

Galustian, Christine, Marie‐Christine Labarthe, J. Blake Bartlett, & Angus Dalgleish. (2004). Thalidomide-derived immunomodulatory drugs as therapeutic agents. Expert Opinion on Biological Therapy. 4(12). 1963–1970. 35 indexed citations

20.

Bartlett, J. Blake, Ian Clarke, Keith Dredge, et al.. (2004). Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers. British Journal of Cancer. 90(5). 955–961. 123 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact